Sareum Hldgs Plc (LON:SAR)
24.17p+0.69%
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Widening losses and toxicology delays threaten cash runway; licensing hopes remain distant for this tiny biotech.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical tria…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £28.4M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Sareum Hldgs Plc and 1,600+ UK and US stocks.
Start free